{"id":"https://openalex.org/W2076950853","doi":"https://doi.org/10.2146/ajhp090563","title":"Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistantStaphylococcus aureus","display_name":"Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistantStaphylococcus aureus","publication_year":2010,"publication_date":"2010-06-01","ids":{"openalex":"https://openalex.org/W2076950853","doi":"https://doi.org/10.2146/ajhp090563","mag":"2076950853","pmid":"https://pubmed.ncbi.nlm.nih.gov/20516473"},"language":"en","primary_location":{"id":"doi:10.2146/ajhp090563","doi":"https://doi.org/10.2146/ajhp090563","is_oa":false,"landing_page_url":"https://doi.org/10.2146/ajhp090563","pdf_url":null,"source":{"id":"https://openalex.org/S105051383","display_name":"American Journal of Health-System Pharmacy","issn_l":"1079-2082","issn":["1079-2082","1535-2900"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Health-System Pharmacy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112939595","display_name":"Yoojung Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I39422238","display_name":"University of Illinois Chicago","ror":"https://ror.org/02mpq6x41","country_code":"US","type":"education","lineage":["https://openalex.org/I39422238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yoojung Yang","raw_affiliation_strings":["Center for Pharmacoeconomic Research, University of Illinois at Chicago (UIC), Chicago"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Pharmacoeconomic Research, University of Illinois at Chicago (UIC), Chicago","institution_ids":["https://openalex.org/I39422238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012855112","display_name":"Martin V. McBride","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin V. McBride","raw_affiliation_strings":["Pharmacy Services, Operations Department, Broadlane Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Services, Operations Department, Broadlane Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055269054","display_name":"Keith A. Rodvold","orcid":"https://orcid.org/0000-0002-7200-7346","observed_orcids":["https://orcid.org/0000-0002-7200-7346"]},"institutions":[{"id":"https://openalex.org/I39422238","display_name":"University of Illinois Chicago","ror":"https://ror.org/02mpq6x41","country_code":"US","type":"education","lineage":["https://openalex.org/I39422238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith A. Rodvold","raw_affiliation_strings":["Department of Pharmacy Practice, UIC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Practice, UIC","institution_ids":["https://openalex.org/I39422238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066166630","display_name":"Frank P. Tverdek","orcid":"https://orcid.org/0000-0001-7510-5470","observed_orcids":["https://orcid.org/0000-0001-7510-5470"]},"institutions":[{"id":"https://openalex.org/I2802034949","display_name":"Saint Louis University Hospital","ror":"https://ror.org/01v49sd11","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801580383","https://openalex.org/I2802034949"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Tverdek","raw_affiliation_strings":["Department of Pharmacy Services, Tenet\u2013Saint Louis University Hospital, St. Louis, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Services, Tenet\u2013Saint Louis University Hospital, St. Louis, MO","institution_ids":["https://openalex.org/I2802034949"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007714381","display_name":"Anne Marie Trese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391012632","display_name":"Forest Laboratories (United States)","ror":"https://ror.org/01p3wva84","country_code":"US","type":"company","lineage":["https://openalex.org/I4391012632"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Marie Trese","raw_affiliation_strings":["Infectious Disease, Forest Research Institute, Jersey City, NJ; when this article was written, she was Director, The Preference Group, Broadlane Inc","when this article was written, she was Director, The Preference Group, Broadlane Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infectious Disease, Forest Research Institute, Jersey City, NJ; when this article was written, she was Director, The Preference Group, Broadlane Inc","institution_ids":["https://openalex.org/I4391012632"]},{"raw_affiliation_string":"when this article was written, she was Director, The Preference Group, Broadlane Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023183317","display_name":"Joel A. Hennenfent","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joel Hennenfent","raw_affiliation_strings":["Pharmacy Services, Operations Department, Broadlane Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Services, Operations Department, Broadlane Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068708746","display_name":"Gordon D. Schiff","orcid":"https://orcid.org/0000-0002-2821-3994","observed_orcids":["https://orcid.org/0000-0002-2821-3994"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gordon Schiff","raw_affiliation_strings":["Center for Patient Safety Research and Practice, Brigham and Women\u2019s Hospital, and Associate Professor of Medicine, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Patient Safety Research and Practice, Brigham and Women\u2019s Hospital, and Associate Professor of Medicine, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033897197","display_name":"Bruce L. Lambert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I39422238","display_name":"University of Illinois Chicago","ror":"https://ror.org/02mpq6x41","country_code":"US","type":"education","lineage":["https://openalex.org/I39422238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce L. Lambert","raw_affiliation_strings":["Department of Pharmacy Administration, UIC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Administration, UIC","institution_ids":["https://openalex.org/I39422238"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091576969","display_name":"Glen T. Schumock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I39422238","display_name":"University of Illinois Chicago","ror":"https://ror.org/02mpq6x41","country_code":"US","type":"education","lineage":["https://openalex.org/I39422238"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Glen T. Schumock","raw_affiliation_strings":["Center for Pharmacoeconomic Research, UIC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Pharmacoeconomic Research, UIC","institution_ids":["https://openalex.org/I39422238"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5091576969"],"corresponding_institution_ids":["https://openalex.org/I39422238"],"apc_list":{"value":4448,"currency":"USD","value_usd":4448},"apc_paid":null,"fwci":1.8593,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.84501218,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"67","issue":"12","first_page":"1017","last_page":"1024"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":0.0737999975681305,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11000","display_name":"Infection Control in Healthcare","score":0.006899999920278788,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/methicillin-resistant-staphylococcus-aureus","display_name":"methicillin-resistant Staphylococcus aureus","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mrsa-infection-prevention","display_name":"MRSA infection prevention","score":0.7879999876022339},{"id":"https://openalex.org/keywords/active-surveillance-cultures","display_name":"active surveillance cultures","score":0.7139999866485596},{"id":"https://openalex.org/keywords/mrsa-decolonization","display_name":"MRSA decolonization","score":0.9179999828338623},{"id":"https://openalex.org/keywords/antimicrobial-stewardship","display_name":"antimicrobial stewardship","score":0.9829999804496765},{"id":"https://openalex.org/keywords/vancomycin","display_name":"vancomycin","score":0.671999990940094},{"id":"https://openalex.org/keywords/linezolid","display_name":"linezolid","score":0.7129999995231628},{"id":"https://openalex.org/keywords/daptomycin","display_name":"daptomycin","score":0.9900000095367432},{"id":"https://openalex.org/keywords/tigecycline","display_name":"tigecycline","score":1.0},{"id":"https://openalex.org/keywords/acute-care-hospitals","display_name":"acute care hospitals","score":0.7070000171661377},{"id":"https://openalex.org/keywords/hospital-policy","display_name":"hospital policy","score":0.5609999895095825}],"concepts":[{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.8248109817504883},{"id":"https://openalex.org/C2781414143","wikidata":"https://www.wikidata.org/wiki/Q411377","display_name":"Linezolid","level":5,"score":0.807219922542572},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7543444633483887},{"id":"https://openalex.org/C2776040555","wikidata":"https://www.wikidata.org/wiki/Q19903321","display_name":"Antimicrobial stewardship","level":4,"score":0.6660839319229126},{"id":"https://openalex.org/C2777052132","wikidata":"https://www.wikidata.org/wiki/Q595158","display_name":"Methicillin-resistant Staphylococcus aureus","level":4,"score":0.5900333523750305},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.5842123031616211},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5588708519935608},{"id":"https://openalex.org/C2777027569","wikidata":"https://www.wikidata.org/wiki/Q420595","display_name":"Tigecycline","level":3,"score":0.514958918094635},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4443241059780121},{"id":"https://openalex.org/C2780182762","wikidata":"https://www.wikidata.org/wiki/Q1630279","display_name":"Guideline","level":2,"score":0.4285178482532501},{"id":"https://openalex.org/C166888038","wikidata":"https://www.wikidata.org/wiki/Q4118322","display_name":"Infection control","level":2,"score":0.4271131753921509},{"id":"https://openalex.org/C4937899","wikidata":"https://www.wikidata.org/wiki/Q68541106","display_name":"Antimicrobial","level":2,"score":0.4089937210083008},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.3614162802696228},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.31074994802474976},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.2624266743659973},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23603114485740662},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.20824214816093445},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.09193873405456543},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069349","descriptor_name":"Linezolid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000078304","descriptor_name":"Tigecycline","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000081","descriptor_name":"Acetamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002985","descriptor_name":"Clinical Protocols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005572","descriptor_name":"Formularies, Hospital as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006761","descriptor_name":"Hospitals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008911","descriptor_name":"Minocycline","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D008911","descriptor_name":"Minocycline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010356","descriptor_name":"Patient Isolation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010607","descriptor_name":"Pharmacy Service, Hospital","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013203","descriptor_name":"Staphylococcal Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013203","descriptor_name":"Staphylococcal Infections","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D013203","descriptor_name":"Staphylococcal Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016134","descriptor_name":"Organizational Policy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017053","descriptor_name":"Infection Control","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017408","descriptor_name":"Guidelines as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017576","descriptor_name":"Daptomycin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019538","descriptor_name":"Health Care Surveys","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023303","descriptor_name":"Oxazolidinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D055624","descriptor_name":"Methicillin-Resistant Staphylococcus aureus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.2146/ajhp090563","doi":"https://doi.org/10.2146/ajhp090563","is_oa":false,"landing_page_url":"https://doi.org/10.2146/ajhp090563","pdf_url":null,"source":{"id":"https://openalex.org/S105051383","display_name":"American Journal of Health-System Pharmacy","issn_l":"1079-2082","issn":["1079-2082","1535-2900"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Health-System Pharmacy","raw_type":"journal-article"},{"id":"pmid:20516473","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20516473","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G5661123105","display_name":"TOOLS FOR OPTIMIZING PRESCRIBING, MONITORING AND EDUCATION","funder_award_id":"U18HS016973","funder_id":"https://openalex.org/F4320332177","funder_display_name":"Agency for Healthcare Research and Quality"}],"funders":[{"id":"https://openalex.org/F4320332177","display_name":"Agency for Healthcare Research and Quality","ror":"https://ror.org/03jmfdf59"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1835445007","https://openalex.org/W1977518261","https://openalex.org/W1995636709","https://openalex.org/W2006537115","https://openalex.org/W2012706218","https://openalex.org/W2036129782","https://openalex.org/W2042478995","https://openalex.org/W2068489935","https://openalex.org/W2103582474","https://openalex.org/W2113265945","https://openalex.org/W2115044119","https://openalex.org/W2116352191","https://openalex.org/W2118546214","https://openalex.org/W2119099576","https://openalex.org/W2121259468","https://openalex.org/W2124502224","https://openalex.org/W2125675160","https://openalex.org/W2127485648","https://openalex.org/W2133120422","https://openalex.org/W2137218933","https://openalex.org/W2140147718","https://openalex.org/W2140643555","https://openalex.org/W2143206150","https://openalex.org/W2149823570","https://openalex.org/W2151584197","https://openalex.org/W2154909081","https://openalex.org/W2157177676","https://openalex.org/W2163392158","https://openalex.org/W2166356134","https://openalex.org/W2166425259","https://openalex.org/W2168908910","https://openalex.org/W2205919670","https://openalex.org/W2417572114","https://openalex.org/W4211194064","https://openalex.org/W4241768922","https://openalex.org/W4253391147"],"related_works":["https://openalex.org/W7168295817","https://openalex.org/W3147473487","https://openalex.org/W2409256631","https://openalex.org/W2095311466","https://openalex.org/W2981664764","https://openalex.org/W2117426734","https://openalex.org/W2136834565","https://openalex.org/W2354704735","https://openalex.org/W1987786382","https://openalex.org/W3195863095"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1],"use":[2,172,199],"of":[3,12,22,41,45,53,103,146,155,173,200,230,235],"policies":[4,98,227],"and":[5,10,18,125,179,190,228,233],"practices":[6,229],"regarding":[7],"surveillance,":[8,231],"decolonization,":[9,232],"treatment":[11,145,234],"methicillin-resistant":[13],"Staphylococcus":[14],"aureus":[15],"(MRSA)":[16],"infections":[17],"the":[19,39,104,110,120,128,138,144,156,171,198,221],"formulary":[20,111,129],"status":[21],"various":[23,147],"antimicrobial":[24,83,93,142],"agents":[25],"used":[26,141],"to":[27,38,204],"treat":[28],"MRSA":[29,96,148,236],"were":[30,51,61,71,240],"characterized.":[31],"METHODS:":[32],"A":[33],"61-item":[34],"questionnaire":[35],"was":[36,108,137],"sent":[37],"director":[40],"pharmacy":[42],"at":[43,74,183],"each":[44],"263":[46],"acute":[47],"care":[48,218],"hospitals":[49,65,76,114,132,158,219],"that":[50],"members":[52],"a":[54,91,161,201,206],"national":[55,243],"group":[56],"purchasing":[57],"organization.":[58],"RESULTS:":[59],"Responses":[60],"received":[62],"from":[63],"102":[64],"(38.8%).":[66],"Active":[67],"surveillance":[68],"culture":[69],"protocols":[70],"in":[72,81,100,112,130,167,220,225],"place":[73],"44":[75],"(44%).":[77],"Nearly":[78,153],"75%":[79],"engaged":[80],"key":[82],"stewardship":[84,94],"activities,":[85],"while":[86,119],"only":[87],"18%":[88],"reported":[89,159],"having":[90,160],"formal":[92],"team.":[95],"decolonization":[97],"existed":[99],"approximately":[101],"25%":[102],"respondent":[105,157],"hospitals.":[106],"Vancomycin":[107,136],"on":[109,127],"all":[113],"with":[115,134,242],"few":[116],"restriction":[117],"policies,":[118],"newer":[121],"anti-MRSA":[122],"agents-linezolid,":[123],"daptomycin,":[124],"tigecycline-were":[126],"most":[131,139,239],"but":[133,238],"restrictions.":[135],"commonly":[140],"for":[143,177,186,212],"infections,":[149,237],"followed":[150],"by":[151],"linezolid.":[152],"70%":[154],"vancomycinspecific":[162],"dosing":[163,178],"or":[164,210],"monitoring":[165,188],"guideline":[166,244],"place.":[168],"Most":[169,193],"specified":[170],"actual":[174],"body":[175],"weight":[176],"trough":[180,209],"serum":[181],"concentrations":[182],"steady":[184],"state":[185],"therapeutic":[187],"(84%":[189],"91%,":[191],"respectively).":[192],"guidelines":[194],"did":[195],"not":[196],"address":[197],"loading":[202],"dose":[203],"attain":[205],"high":[207],"target":[208],"methods":[211],"choosing":[213],"alternative":[214],"agents.":[215],"CONCLUSION:":[216],"Acute":[217],"United":[222],"States":[223],"varied":[224],"their":[226],"consistent":[241],"recommendations.":[245]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}